Metropolis Healthcare Limited (METROPOLIS) Q2 FY27 Financial Results: PAT ₹57 & Revenue ₹450 Cr

Investor Takeaways

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

What Changed

Metropolis Healthcare reported robust Q1FY27 results, with revenue up 17% YoY to ₹450 crore and EBITDA up 27% YoY to ₹113 crore. PAT increased 26% YoY to ₹57 crore, supported by margin expansion and operational efficiency. The EBITDA margin expansion of 210 bps indicates improved profitability. Growth was broad-based, with strong performance across B2C and B2B segments, particularly in Tier III cities (25% YoY growth) and specialty diagnostics. Management highlighted sustainable growth through innovation and network expansion. The company’s focus on premium service adoption and operational scaling appears to be yielding results, as evidenced by rising profitability metrics alongside revenue growth.

Peer Comparison

Metropolis Healthcare trades at a higher P/E multiple compared to Sun Pharmaceutical and Divi's Laboratories, suggesting market expectations of higher future growth. However, its ROE and ROCE are not provided in the current filing, limiting direct profitability comparison. The company’s market capitalization is significantly lower than Sun Pharmaceutical but comparable to Divi's Laboratories in scale.

Risks & Concerns

Quarterly Trend

The company’s revenue in Q1FY27 (₹450 Cr) shows a significant sequential and YoY increase compared to previous quarters, indicating accelerating growth momentum. Net profit and OPM trends in prior quarters suggest improving operational efficiency, which appears to have translated into stronger PAT growth in Q1FY27. The upward trajectory in profitability metrics supports the positive tone of the current filing.

📄 View Original Announcement (PDF)

About Metropolis Healthcare Limited (METROPOLIS)

Healthcare · Healthcare · Listed on NSE

View full METROPOLIS stock details →